Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.45 |
| ▸ | CA2 | P00918 | 9/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | GRK6 | P43250 | 2/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8711595 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL788634 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7030562 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL11289015 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL38256 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7198908 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL4278638 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL319584 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL4704343 | 1.00 | TSHR (0.46) | TSHRCA1CA2GSK3BNPC1 | |
| SCHEMBL7528649 | 0.99 | TSHR (0.48) | TSHRCA1CA2GSK3BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716745-A1 | NEW TLR-4 ANTAGONIST APTAMERS | Merck Patent GmbH (DE) | 2026-04-01 | — | — | EP | disclosed |
| WO-2024240750-A1 | NEW TLR-4 ANTAGONIST APTAMERS | APTATARGETS, S.L. (ES) | 2024-11-28 | — | — | WO | disclosed |
| EP-3244922-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | Agrawal, Babita (CA) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016187312-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ALPHAVIRUS INFECTION | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016112459-A1 | METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS | AGRAWAL BABITA (CA) | 2016-07-21 | — | — | WO | disclosed |
| WO-2012037485-A2 | METHODS OF INHIBITING ALPHAVIRUS REPLICATION AND TREATING ALPHAVIRUS INFECTION | 1THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-2408448-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408449-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | The Board Of Trustees Of The University Of the Leland Stanford Junior University (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2341924-A2 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | The J. David Gladstone Institutes (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010107742-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-1680137-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | Intermune, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006020580-A2 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006016930-A2 | METHODS FOR TREATING HCV INFECTION | INTERMUNE, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005110455-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005067963-A1 | USE OF POLYETHYLENE GLYCOL-MODIFIED INTERFERON-ALPHA IN THERAPEUTIC DOSING REGIMENS | INTERMUNE, INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005067454-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C VIRUS INFECTION | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005062949-A2 | METHOD FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |